Home
    • Plans Blog Contact
    Pmv Pharmaceuticals Inc logo

    Pmv Pharmaceuticals Inc

    PMVP
    Last price US$1.24
    Market cap US$74.7m
    12M price change -13.33%
    Loading the 12-month Mave Thesis and 1-month news signal

    Industry and sector peers, plus broader research alternatives

    View comparison
    Syneos HealthSYNH Industry peer Pluri IncPLUR Industry peer Prenetics Global LtdPRE Industry peer Zoetis IncZTS Sector peer
    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    Pmv Pharmaceuticals Inc Overview

    Industry: Biotechnology & Medical Research

    Sector: Healthcare

    PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing Wild-type p53 or other p53 mutations, including R273H, R273C, R175H, G245S, R248Q, and R282W, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey. PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutati Read More

    Mavefund brings filings, fundamentals, valuation, price history and news for Pmv Pharmaceuticals Inc into one research view. The sections below show what strengthens or weakens the research case.

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed May 12, 2026

    Quarterly result summary

    Net loss was -$18M (from $17.4M). G&A expense was $3.7M.

    Net loss -$18M from $17.4M
    G&A expense $3.7M reported
    Cash $93.5M reported

    What changed

    • Net loss was -$18M (from $17.4M).

    Guidance / outlook

    No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.

    Earnings release Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing 8-K May 12, 2026 SEC filing 10-Q May 12, 2026 SEC filing 10-K Mar 06, 2026 SEC filing 8-K Mar 06, 2026 Earnings release Earnings release Mar 06, 2026 SEC filing 8-K Nov 12, 2025 Earnings material Earnings release Nov 12, 2025 SEC filing 10-Q Nov 12, 2025 SEC filing 10-Q Aug 07, 2025 SEC filing 8-K Aug 07, 2025 Earnings release Earnings release Aug 07, 2025

    Prediction-grade evidence

    Recent News

    Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

    No qualified company news in the last 14 days

    No recent article passed both the company-relevance and source-reliability checks. Research continues to use the other available filings, fundamentals, market data, and valuation inputs.

    Earnings Per Share

    Score 4.00/5
    Pmv Pharmaceuticals Inc boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Biotechnology & Medical Research industry , Syneos Health , Pluri Inc , Prenetics Global Ltd are companies with high ratings.

    Return on Equity

    Score 1.80/5
    Pmv Pharmaceuticals Inc exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Pmv Pharmace... PMVP US$74.7m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 2.21/5
    Pmv Pharmaceuticals Inc olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Pmv Pharmace... PMVP US$74.7m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Biotechnology & Medical Research industry , Syneos Health , Pluri Inc , Prenetics Global Ltd are companies with high ratings.

    Leverage

    Score 4.02/5
    Pmv Pharmaceuticals Inc attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc , also exhibit high scores.
    Pmv Pharmace... PMVP US$74.7m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    Verified SEC statements load when this section enters view.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    Pmv Pharmaceuticals Inc logo

    Pmv Pharmaceuticals Inc

    US$1.24

    US$74.7m

    -7.14%

    -13.33%